Drug intelligence / Profile preview

LGD3

Development stage: Preclinical
Lead developer: Viking Therapeutics
Modality: Small Molecules
Administration: Injection

Overview

LGD3 is a uridine-based paramagnetic self-assembled amphiphilic molecule designed as a T1 magnetic resonance imaging (MRI) contrast agent. It features a DTTA binding site and exhibits high relaxivity in solution, which is further enhanced in the presence of human serum albumin. LGD3 demonstrates high specificity for hepatocytes, leading to a significant increase in contrast-to-noise ratio in T1-weighted MR images of the liver, enabling the detection of small hepatocellular carcinoma lesions.

Beyond the preview

Go deeper on LGD3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LGD3.

Explore the full profile